<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-five evaluable pediatric patients with histologically proven Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> were treated with moderate dose combination chemotherapy consisting of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (COMA regime) without central <z:mp ids='MP_0008912'>nervous</z:mp> system prophylaxis </plain></SENT>
<SENT sid="1" pm="."><plain>Complete remission was achieved in 94.1% (16/17) of patients with Stage I, I R, II and III A disease, with disease-free survival of more than 3 years </plain></SENT>
<SENT sid="2" pm="."><plain>This protocol was attended by minimal chemotherapeutic toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>This combination chemotherapy was ineffective in more advanced disease (Stages III B, IV), major cause of failure being progressive disease with central <z:mp ids='MP_0008912'>nervous</z:mp> system involvement </plain></SENT>
<SENT sid="4" pm="."><plain>This study showed the effectiveness of moderate dose chemotherapy without <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis in early stage Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> including Stage III A and needs for aggressive chemotherapy with <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> prophylaxis in more advanced disease </plain></SENT>
</text></document>